Filing Flows

Filing Flows › Companies › Acadia Pharmaceuticals › Cash flow

Acadia Pharmaceuticals cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$10.3M in Q3 2026 · $82.0M over twelve months

Operating cash flow$11.5M
Capital spending−$1.2M
Free cash flow+$10.3M
Cash / net income0.2×
Cash conversion cycle245 days

Analysis

In Q3 2026, Acadia Pharmaceuticals generated $11.5M of operating cash flow and spent $1.2M on capital projects, leaving free cash flow of $10.3M. That is $63.6M less than in Q3 2025 ($73.9M).

Over the twelve months to Sep 30, 2026, operating cash flow was $97.5M; the largest uses were other investing ($68.7M), capital spending ($15.5M); besides operations, cash came from shares issued ($49.3M); the cash balance rose by $62.7M.

Operating cash flow was $11.5M against net income of $53.5M — 0.2× profit, less cash than reported earnings, worth checking against working capital. The largest differences: accrued liabilities −$36.5M, payables −$28.2M, stock-based pay +$17.5M.

Its cash conversion cycle was 245 days (receivables 42 + inventory 283 − payables 80).

Free cash flow

Acadia Pharmaceuticals: free cash flow by quarterAcadia Pharmaceuticals: free cash flow by quarter$39.9MQ4 2024$20.3MQ1 2025$63.7MQ2 2025$73.9MQ3 2025−$52.7MQ4 2025$28.8MQ1 2026$95.7MQ2 2026$10.3MQ3 2026
Operating cash flow less capital spending.
Acadia Pharmaceuticals: operating cash flow against capital spendingAcadia Pharmaceuticals: operating cash flow against capital spendingOperating cash flowCapital spending$40.4M$453KQ4 2024$20.3M$0Q1 2025$64.0M$297KQ2 2025$74.3M$388KQ3 2025−$48.7M$4.0MQ4 2025$34.0M$5.2MQ1 2026$101M$5.1MQ2 2026$11.5M$1.2MQ3 2026
Latest (Q3 2026): Operating cash flow $11.5M, Capital spending $1.2M.

Capital allocation, year by year

Acadia Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearAcadia Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY2021: Operating cash flow −$126MFY2021: Shares issued $31.1MFY2021: Capital spending −$1.1M$31.1MFY2021FY2022: Operating cash flow −$114MFY2022: Shares issued $11.9M$11.9MFY2022FY2023: Operating cash flow $16.7MFY2023: Shares issued $45.4MFY2023: Capital spending −$50K$62.1MFY2023FY2024: Operating cash flow $158MFY2024: Shares issued $6.8MFY2024: Capital spending −$523K$165MFY2024FY2025: Operating cash flow $110MFY2025: Shares issued $49.9MFY2025: Capital spending −$4.7M$160MFY2025
Over these 5 years operating cash flow totalled $44.6M; the largest uses were operating cash flow ($240M) and capital spending ($6.4M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$976M
Debtnone
Net cash$976M

Acadia Pharmaceuticals funds itself: free cash flow was $82.0M over the last twelve months, with $976M of cash and investments and no debt on the balance sheet.

Where the cash came from and went

Acadia Pharmaceuticals: sources (+) and uses (−) of cash, Q3 2026Acadia Pharmaceuticals: sources (+) and uses (−) of cash, Q3 2026Other investing−$84.9MCash drawn (+) / kept (−)$62.6MShares issued$11.9MOperating cash flow$11.5MCapital spending−$1.2MExchange rates$159K
Acadia Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q3 2026Acadia Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow$97.5MOther investing−$68.7MCash drawn (+) / kept (−)−$62.7MShares issued$49.3MCapital spending−$15.5MExchange rates$218K

From profit to cash

Acadia Pharmaceuticals: net income to operating cash flow, Q3 2026Acadia Pharmaceuticals: net income to operating cash flow, Q3 2026Net income$53.5MDepreciation & amortization$3.7MStock-based pay$17.5MDeferred taxes$14.4MReceivables−$10.4MInventory$1.4MPayables−$28.2MAccrued liabilities−$36.5MPrepaid and other assets$228KOther liabilities$1.8MOperating cash flow$11.5M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 20264228380245
Q2 20264235591306
Q1 20264340642407
Q4 20253838157362
Q3 20253746089408
Q2 20253746984421
Q1 20253843076392
Q4 20243537674337

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$11.5M−$1.2M$11.9M$62.6M$10.3M
Q2 2026$101M−$5.1M$10.5M−$103M$95.7M
Q1 2026$34.0M−$5.2M$4.2M−$105M$28.8M
Q4 2025−$48.7M−$4.0M$22.7M$81.9M−$52.7M
Q3 2025$74.3M−$388K$9.4M−$4.4M$73.9M
Q2 2025$64.0M−$297K$16.0M−$36.6M$63.7M
Q1 2025$20.3M—$1.8M$102M$20.3M
Q4 2024$40.4M−$453K$2.0M−$164M$39.9M

Acadia Pharmaceuticals: income statement and cash flow

Acadia Pharmaceuticals, Q3 2026: revenue $342M (+23% year over year), operating margin 21.0%. The chart follows the revenue to costs, profit and cash.

Acadia Pharmaceuticals: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.